CN1263457C - 绞股蓝总皂苷口腔崩解片及其制备工艺 - Google Patents
绞股蓝总皂苷口腔崩解片及其制备工艺 Download PDFInfo
- Publication number
- CN1263457C CN1263457C CN 200410058041 CN200410058041A CN1263457C CN 1263457 C CN1263457 C CN 1263457C CN 200410058041 CN200410058041 CN 200410058041 CN 200410058041 A CN200410058041 A CN 200410058041A CN 1263457 C CN1263457 C CN 1263457C
- Authority
- CN
- China
- Prior art keywords
- herb gynostemmae
- gynostemmae pentaphylli
- disintegrating tablet
- pentaphylli total
- orally disintegrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000011248 coating agent Substances 0.000 claims abstract description 19
- 238000000576 coating method Methods 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 15
- 239000000945 filler Substances 0.000 claims abstract description 8
- 239000000314 lubricant Substances 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 18
- 229930182490 saponin Natural products 0.000 claims description 18
- 150000007949 saponins Chemical class 0.000 claims description 18
- 235000017709 saponins Nutrition 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 241000208340 Araliaceae Species 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 10
- 235000008434 ginseng Nutrition 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 239000000605 aspartame Substances 0.000 claims description 9
- 229960003438 aspartame Drugs 0.000 claims description 9
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- 108010011485 Aspartame Proteins 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 6
- 235000010357 aspartame Nutrition 0.000 claims description 6
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 6
- 230000000873 masking effect Effects 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 241000207199 Citrus Species 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 235000020971 citrus fruits Nutrition 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 2
- 239000004378 Glycyrrhizin Substances 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 229910000503 Na-aluminosilicate Inorganic materials 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 229940014259 gelatin Drugs 0.000 claims description 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 239000000429 sodium aluminium silicate Substances 0.000 claims description 2
- 235000012217 sodium aluminium silicate Nutrition 0.000 claims description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 229940109275 cyclamate Drugs 0.000 claims 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 abstract description 28
- 150000002338 glycosides Chemical class 0.000 abstract description 28
- 239000003826 tablet Substances 0.000 abstract description 25
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract description 13
- 239000006191 orally-disintegrating tablet Substances 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 4
- 208000026435 phlegm Diseases 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 206010019233 Headaches Diseases 0.000 abstract description 2
- 206010033557 Palpitations Diseases 0.000 abstract description 2
- 208000009205 Tinnitus Diseases 0.000 abstract description 2
- 231100000869 headache Toxicity 0.000 abstract description 2
- 231100000886 tinnitus Toxicity 0.000 abstract description 2
- 241001065361 Gynostemma Species 0.000 abstract 6
- 210000000952 spleen Anatomy 0.000 abstract 2
- 206010000060 Abdominal distension Diseases 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000031091 Amnestic disease Diseases 0.000 abstract 1
- 206010002660 Anoxia Diseases 0.000 abstract 1
- 241000976983 Anoxia Species 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 208000000059 Dyspnea Diseases 0.000 abstract 1
- 206010013975 Dyspnoeas Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 206010040007 Sense of oppression Diseases 0.000 abstract 1
- 208000012886 Vertigo Diseases 0.000 abstract 1
- 208000019790 abdominal distention Diseases 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 230000006986 amnesia Effects 0.000 abstract 1
- 230000007953 anoxia Effects 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 208000034783 hypoesthesia Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 208000013220 shortness of breath Diseases 0.000 abstract 1
- 230000002269 spontaneous effect Effects 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 230000035900 sweating Effects 0.000 abstract 1
- 231100000889 vertigo Toxicity 0.000 abstract 1
- 210000000214 mouth Anatomy 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- -1 tetracyclic triterpenoids compound Chemical class 0.000 description 6
- 235000015165 citric acid Nutrition 0.000 description 5
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 5
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 4
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 102100031013 Transgelin Human genes 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 150000008131 glucosides Chemical class 0.000 description 4
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920003149 Eudragit® E 100 Polymers 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000012991 uterine carcinoma Diseases 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 101100273639 Carassius auratus ccna1 gene Proteins 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种具有降血脂、改善心肌缺血缺氧、脑缺血的保护、抗氧化等作用;可以养心健脾、益气和血、除痰化瘀;适用于高脂血症,见有心悸气短、胸闷肢麻、眩晕头痛、健忘耳鸣、自汗乏力、或脘腹胀满等心脾气虚,痰阻血瘀等症的绞股蓝总苷口腔崩解片及其制备工艺。本发明的目的在于弥补现有的绞股蓝总苷制剂剂型的不足,向广大患者和医务工作者提供一种服用方便、吸收起效快的绞股蓝总苷口腔崩解片及其制备工艺。以绞股蓝总苷为原料,填充剂、崩解剂、矫味剂、助流剂、润滑剂等为辅料,根据不同情况可使用粘合剂或包衣材料,也可酌情加入适量泡腾剂,再经过特定的制备方法制备,采用压片机压片即得。本发明的口腔崩解片脆碎度良好,崩解迅速,口感好,无砂砾感,不需要特殊的生产条件;具有生产成本低,携带、储藏、运输和服用方便等特点;特别之处是可以在无水条件下服用并快速起效,从而改善患者的依从性,提高药物的疗效。
Description
[技术领域]
本发明涉及一种适用于高脂血症,见有心悸气短、胸闷肢麻、眩晕头痛、健忘耳鸣、自汗乏力、或脘腹胀满等心脾气虚,痰阻血瘀等症的绞股蓝总苷口腔崩解片制剂。
[背景技术]
绞股蓝[gynostemma pentaphyllum(thunb)mak]系双子叶纲葫芦科绞股蓝属植物。中药名为七叶胆。在日本,被誉为“福音草”。内含多种对人体有益的皂甙、维生素和氨基酸。研究表明,绞股蓝活性成份具有降血脂、降血糖、抗肿瘤、抗衰老、保护肝脏及增强肌体免疫功能等作用。对高脂血症、高血压、冠心病等心血管系统疾患、糖尿病、肿瘤等病症具有良好的防治效果。制作保健饮品饮用,味道纯正且极具保健价值,长期饮用无毒副作用,被誉为中国“南方人参”“抗癌新秀”。
祖国医学认为,绞股蓝味苦、性寒、无毒。民间多用于消炎解毒、止咳祛痰,产区群众在夏季采其茎叶煎水作清凉饮料。1972年,云南省曲靖地区中西医结合小组首次将绞股蓝应用于临床,每日剂量2.5-3克,每日3次水煎服,10日为一疗程,共治疗老年慢性气管炎537例。其中临床治愈25例,显效133例,好转266例,总有效率79%,一般无副作用。
据化验分析,绞股蓝除含有甾醇、糖份、色素外,还有50多种皂甙,包括四环三萜化合物,其中七叶胆皂甙III、IV、VII、XII四种,分别与人参皂甙Rb1、Rb3、Rd、F2是同一物质;其酸水解产物与人参皂甙的酸水解产物——人参二醇具有相同的理化性质。这在非五加科的植物中是非常罕见的,因而被誉为“第二人参”。
1982年,日本学者小田岛肃夫等的实验表明,七叶胆皂甙对肝癌、肺癌、子宫癌、皮肤癌等癌细胞的增殖,有明显的抑制作用。日本药理试验和临床应用证实,绞股蓝不仅对人体有滋补、镇静、催眠、抗紧张、促食欲、降血脂、降胆固醇、降转氨酶、延缓衰老等作用,还能防止正常细胞癌化并使癌细胞转化为正常细胞。临床上可用于肺癌、胃癌、肝癌、食道癌、胆囊癌、直肠癌、胰腺癌、乳腺癌和子宫癌等20多种癌症,还能防治心血管疾病,改普肥胖症,防治乙型肝炎、肝硬化、胃和十二指肠溃疡,治疗偏头痛、白发、失眠症、不定愁诉症等。从而展现了广阔的药用前景。
现有的绞股蓝总苷制剂的剂型有:滴丸、硬胶囊、软胶囊和普通片。
由于剂型的原因,使大多数口服制剂服用时需要大量的水送下,这使得许多老年人、婴幼儿或者吞咽困难、取水不便的患者难以服用。注射液又往往容易产生过敏反应或不良反应等,同时注射液还存在着操作难度大,患者痛苦也大,制造和医疗成本高,患者经济负担重的缺点。因此,有必要制备服用更加方便的剂型以满足临床治疗和家庭使用的多种需要。
[发明内容]
本发明的目的在于改进现有的绞股蓝总苷在口服剂型方面的不足,向广大患者和医务工作者提供一种服用方便、吸收起效快、生物利用度高的绞股蓝总苷口腔崩解片制剂。本发明涉及服用时不必饮水、在口腔中仅需几十秒即可迅速崩解或溶解、随唾液下咽即可完成服药的绞股蓝总苷口腔崩解片及其制备方法。
一、处方
本发明所述及的绞股蓝总苷口腔崩解片,包括原料药物绞股蓝总苷,共需要以下9类原、辅材料,其中:不作包衣处理时,则不使用包衣材料,泡腾剂为酌情可选用辅料,也可不用。
绞股蓝总苷(5-50)%,粘合剂(0-5)%,填充剂(10-80)%,崩解剂(2-35)%,矫味剂(1-40)%,包衣材料(0-40)%,泡腾剂(0-30)%,助流剂(0.01-5)%,润滑剂(0.3-3)%。
其中:
粘合剂包括但不仅限于淀粉、预胶化淀粉、糊精、麦芽糖糊精、蔗糖、阿拉伯胶、明胶、甲基纤维素、羧甲基纤维素、乙基纤维素、聚乙烯醇、聚乙二醇、聚乙烯吡咯烷酮(PVP)、海藻酸及海藻酸盐、黄原胶、羟丙基纤维素和羟丙基甲基纤维素(HPMC),可单独使用,也可组合使用。
填充剂包括但不仅限于甘露醇(粒状或粉状)、木糖醇、山梨醇、麦芽糖、赤藓醇、微晶纤维素、PROSOLV SMCC、聚合糖(EMDEX)、偶合糖、葡萄糖、乳糖、蔗糖、糊精和淀粉等,可以单独使用,也可以组合应用,用量通常为(10-80)%。
崩解剂包括但不仅限于交联聚乙烯吡咯烷酮(PVPP)、羧甲基淀粉钠(CMS-Na)、低取代羟丙基甲基纤维素(L-HPC)、交联羧甲基纤维素钠(CCNa)和大豆多糖(EMCOSOY)等,可单独使用,也可组合使用。
矫味剂包括但不仅限于甘露醇、木糖醇、甜菊甙、乳糖、果糖、蔗糖、蛋白糖、麦芽糖醇、甘草甜素、环己氨基磺酸钠、明胶、阿斯巴甜、香蕉香精、菠萝香精、香兰素、香橙香精、桔子香精、薄荷香精、人参香精、草莓香精、枸橼酸、柠檬酸等,可单独使用,也可组合使用。
包衣材料包括但不仅限于明胶、阿拉伯胶、海藻酸盐、壳聚糖、羧甲基纤维素盐、醋酸纤维素酞酸酯、乙基纤维素、甲基纤维素、羟丙甲纤维素、丙烯酸树脂类(国产丙烯酸树脂I、II、III、IV,Eudragit系列)、聚乙烯醇、聚乙烯吡咯烷酮、聚乙二醇等,可单独使用,也可组合使用。
助流剂包括但不仅限于微粉硅胶、滑石粉、Cab-O-sil、Arosil、水合硅铝酸钠等,可单独使用,也可组合使用。
润滑剂包括但不仅限于硬脂酸镁、硬脂酸钙、硬脂酸锌、单硬脂酸甘油脂、聚乙二醇、氢化植物油、硬脂富马酸钠、聚氧乙烯单硬脂酸酯、单月桂蔗糖酸酯、月桂醇硫酸钠、月桂醇硫酸镁、十二烷基硫酸镁和滑石粉等,可单独使用,也可组合使用。
泡腾剂包括但不仅限于苹果酸、柠檬酸或枸橼酸与碳酸氢钠或碳酸钠的混合物。
二、制备方法
本发明所述及的绞股蓝总苷口腔崩解片,其制备方法为直接压片法,具有制备常规片剂的生产厂家均可采用。
绞股蓝总苷味苦,本发明可采用二种不同方法进行矫味或掩味:①采用矫味剂直接矫味;②预先将绞股蓝总苷进行粉末包衣以掩味。
具体制备方法如下:
第一步 绞股蓝总苷的预处理方法:
①直接矫味法——本法对绞股蓝总苷原料进行制粒或不作处理,直接进入
第二步;
②粉末包衣掩味——取所选定的包衣材料,用与之相适应的溶媒溶解并稀释至适当浓度备用,再取绞股蓝总苷置于沸腾床中使沸腾,然后以适当速度喷入上述溶液进行粉末包衣,得绞股蓝总苷粉末包衣颗粒,干燥后过筛备用;
第二步 将矫味剂与绞股蓝总苷或经第一步掩味处理后的原料颗粒按量称取,并混合均匀备用;
第三步 将填充剂、崩解剂、泡腾剂、助流剂按量称取并混合均匀,再与经第二步所得之物料混合使均匀,加入润滑剂混匀备用;
第四步 所得物料经中间体检测,确定片重后,送入压片机压片即得。
[有益效果]
片剂是一种传统剂型,因其质量稳定、剂量准确、服用、携带方便、机械化程度高、生产成本低而成为目前最常用的剂型之一,但因片剂加压成型,崩解较慢、生物利用度较低,且部分患者吞服较为困难,因而片剂的推广使用在一定程度上受到限制。为此口服固体速释制剂成为近年新药研发的一个热点,特别是口腔崩解片,因其服用方便、起效快、生物利用度高、口感好而成为片剂开发的重点。
口腔崩解片是指不需用水或只需少量水,无需咀嚼,片剂置于舌面,遇唾液后迅速崩解,或借吞咽动力,药物即可入胃起效的片剂。口腔崩解片的特点是吸收快、生物利用度高,肠道残留少,副作用低,避免肝脏首过效应等。
据《口腔崩解片的剂型特点和质量控制会议纪要》的要求,口腔崩解片比滴丸和普通片的崩解速度有本质的飞跃,口腔崩解片的崩解一般在30秒以内,最多不超过1分钟。
[具体实施例]
为了更好的说明本发明所述绞股蓝总苷口腔崩解片的制备方法,结合直接矫味法和粉末包衣掩味法分别举一个实施例如下:
实施例一 直接矫味法
一.处方
1.原料——绞股蓝总苷20.0g;
2.粘合剂——聚乙烯吡咯烷酮K-30 0.5g;
3.填充剂——甘露醇58.5g;
PROSOLV SMCC 5.0g;
4.矫味剂——阿斯巴甜1.0g;
人参香精1.0g;
5.崩解剂—交联聚乙烯吡咯烷酮8.0g;
L-HPC 4.0g;
6.助流剂——微粉硅胶1.0g;
7.润滑剂——硬脂富马酸钠1.0g。
总重100g,共制成1000片。
二.制备方法
1)取绞股蓝总苷原料粉碎,用聚乙烯吡咯烷酮K-30制粒,过26目筛,备用;
2)将微粉硅胶、人参香精、PROSOLV SMCC和阿斯巴甜,分别过40目筛,混合均匀,再加入已制粒的绞股蓝总苷颗粒,混合均匀,备用;
3)取甘露醇、L-HPC和交联聚乙烯吡咯烷酮分别过40目筛,混合均匀,再将经矫味的原料加入并混合均匀,最后加入硬脂富马酸钠并混合均匀;
4)中间体含量检测,确定片重后,送入压片机压片即得。
实施例二 粉末包衣掩味法
一.处方
1.原料—绞股蓝总苷20.0g;
2.包衣材料——Eudragit E100 3.5g;
Eudragit NE30D(干)1.5g;
3.填充剂——甘露醇55.5g;
微晶纤维素5.0g;
4.矫味剂——阿斯巴甜1.0g;
人参香精1.0g;
5.崩解剂——交联聚乙烯吡咯烷酮6.0g;
L-HPC 4.0g;
6.助流剂——微粉硅胶1.5g;
7.润滑剂——硬脂富马酸钠1.0g。
总重100g,共制成1000片。
二.制备方法
1)取Eudragit E100和Eudragit NE30D Eudragit NE30D用95%以上的药用工业乙醇溶解并稀释至一定浓度备用;
2)取绞股蓝总苷置于沸腾床中沸腾,按一定速度喷入上述溶液进行粉末包衣,制得绞股蓝总苷粉末包衣颗粒,干燥后备用;
3)将甘露醇、微晶纤维素、微粉硅胶、PVPP、L-HPC、阿斯巴甜、硬脂富马酸钠和人参香精混合均匀,再和过筛后的包衣颗粒混匀备用;
4)中间体含量检测,确定片重后,送入压片机压片即得。
实施例三 泡腾剂矫味法
一.处方
1.原料——绞股蓝总苷20.0g;
2.粘合剂——聚乙烯吡咯烷酮K-30 0.5g;
3.泡腾剂——枸橼酸12.5g;
碳酸氢钠10.0g;
4.填充剂——甘露醇33.0g;
PROSOLV SMCC 5.0g;
5.矫味剂——阿斯巴甜1.0g;
香橙香精1.0g;
6.崩解剂——交联聚乙烯吡咯烷酮10.0g;
L-HPC 5.0g;
7.助流剂——微粉硅胶1.0g;
8.润滑剂——硬脂富马酸钠1.0g。
总重100g,共制成1000片。
二.制备方法
1)取绞股蓝总苷和枸橼酸原料混合后粉碎,用聚乙烯吡咯烷酮K-30制粒,过26目筛,备用;
2)取碳酸氢钠粉碎,用聚乙烯吡咯烷酮K-30制粒,过26目筛,备用;
3)将其余所有的辅料分别过40目筛后混合均匀,再加入已制粒的颗粒,混合均匀,备用;
4)中间体含量检测,确定片重后,送入压片机压片即得。
Claims (7)
1.一种绞股兰总皂苷口腔崩解片,其特征在于其重量组成为绞股兰总皂苷5~50%、包衣材料聚丙烯酸树脂5~40%、崩解剂交联聚乙烯吡咯烷酮和低取代羟丙甲基纤维素共计2~35%、填充剂10-80%、矫味剂1~40%、助流剂0.01~5%、润滑剂0.3~3%组成,其中填充剂选自甘露醇、微晶纤维素、糊精、乳糖、淀粉、麦芽糖糊精和预胶化淀粉中的一种或多种,矫味剂选自甘露醇、乳糖、甜菊甙、明胶、阿斯巴甜、甜蜜素、甘草甜素、香橙香精、桔子香精、薄荷香精、人参香精、草莓香精、枸橼酸、柠檬酸中的一种或多种,助流剂选自微粉硅胶、滑石粉、Cab-O-sil、Arosil、水合硅铝酸钠中的一种或多种,润滑剂选自硬脂酸镁、单硬脂酸甘油脂、十二烷基硫酸镁、滑石粉中、硬脂富马酸钠中的一种或多种;其中将绞股兰总皂苷用包衣材料进行粉末包衣后,所得颗粒与其它辅料一起压制成崩解片。
2.如权利要求1所述的绞股兰总皂苷口腔崩解片,其中填充剂是甘露醇和/或微晶纤维素。
3.如权利要求1所述的绞股兰总皂苷口腔崩解片,其中矫味剂是阿斯巴甜和/或人参香精。
4.如权利要求1所述的绞股兰总皂苷口腔崩解片,其中润滑剂是硬脂富马酸钠。
5.如权利要求1所述的绞股兰总皂苷口腔崩解片,其中助流剂是微粉硅胶。
6.如权利要求1所述的绞股兰总皂苷口腔崩解片,其特征在于其重量组成为:绞股兰总皂苷20份,聚丙烯酸树脂5份,甘露醇55.5份,微晶纤维素5份,阿斯巴甜1份,人参香精1份,交联聚乙烯吡咯烷酮6份,低取代羟丙甲基纤维素4份,微粉硅胶1.5份,硬脂富马酸钠1份。
7..如权利要求1-6任意一项所述的绞股兰总皂苷口腔崩解片的制备方法,其特征在于由以下步骤组成:
第一步绞股兰总皂苷的预处理;取所选定的包衣材料,用与之相适应的溶媒溶解并稀释至适当浓度备用,再取绞股兰总皂苷置于流化床中使沸腾,然后以适当速度喷入上述溶液进行粉末包衣,得绞股兰总皂苷粉末包衣颗粒,干燥后过筛备用;
第二步将矫味剂与绞股兰总皂苷颗粒或经第一步掩味处理后的原料颗粒按量称取,并混合均匀备用;
第三步将填充剂、崩解剂、助流剂按量称取并混合均匀,再与经第二步所得之物料混合使均匀,加入润滑剂混匀,备用;
第四步所得物料经中间体检测。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410058041 CN1263457C (zh) | 2004-08-10 | 2004-08-10 | 绞股蓝总皂苷口腔崩解片及其制备工艺 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410058041 CN1263457C (zh) | 2004-08-10 | 2004-08-10 | 绞股蓝总皂苷口腔崩解片及其制备工艺 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1602882A CN1602882A (zh) | 2005-04-06 |
| CN1263457C true CN1263457C (zh) | 2006-07-12 |
Family
ID=34666237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410058041 Expired - Fee Related CN1263457C (zh) | 2004-08-10 | 2004-08-10 | 绞股蓝总皂苷口腔崩解片及其制备工艺 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1263457C (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100441181C (zh) * | 2006-03-03 | 2008-12-10 | 陕西新药技术开发中心 | 一种治疗高脂血症的丹蓝微丸胶囊药物的制备方法和应用 |
| CN102861035B (zh) * | 2012-10-26 | 2014-04-16 | 吴俊华 | Gypensapogenin B在治疗心肌缺血药物中的应用 |
| CN105147631A (zh) * | 2015-09-28 | 2015-12-16 | 宁夏康亚药业有限公司 | 一种非诺贝酸片及其制备方法 |
-
2004
- 2004-08-10 CN CN 200410058041 patent/CN1263457C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1602882A (zh) | 2005-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101185733B (zh) | 一种健胃消食口腔崩解片及制备方法 | |
| CN113082166A (zh) | 一种以铁皮石斛为原料制备保健食品的方法 | |
| CN1586475A (zh) | 维生素c口腔崩解片及其制备方法 | |
| CN1303989C (zh) | 葡萄糖酸锌口腔崩解片及其制备工艺 | |
| CN1254246C (zh) | 西地那非及其药学上可接受的盐的口腔崩解片及其制备方法 | |
| CN1237981C (zh) | 银杏叶口腔崩解片及其制备方法 | |
| CN1250228C (zh) | 三七总皂苷口腔崩解片及其制备方法 | |
| CN101066438A (zh) | 一种治疗呃逆的药物及制备方法 | |
| CN1263457C (zh) | 绞股蓝总皂苷口腔崩解片及其制备工艺 | |
| CN1247202C (zh) | 薯蓣皂苷口腔崩解片及其制备方法 | |
| CN1245154C (zh) | 中药或天然来源药用物质口腔速崩片及其制备方法 | |
| CN1283267C (zh) | 人参茎叶总皂苷口腔崩解片制剂及其制备方法 | |
| CN1267094C (zh) | 红花黄色素口腔崩解片及其制备工艺 | |
| CN1247195C (zh) | 水飞蓟宾口腔崩解片及其制备工艺 | |
| CN1297263C (zh) | 葡萄糖酸钙口腔崩解片及其制备工艺 | |
| CN1247203C (zh) | 豆腐果苷口腔崩解片及其制备方法 | |
| CN2745572Y (zh) | 环形的中药泡腾剂型 | |
| CN101199615B (zh) | 一种治疗口腔溃疡的外用内服口腔崩解片及其制备方法 | |
| CN107582866B (zh) | 铁皮石斛和氨氯地平在制备治疗高血压药物中的应用方法 | |
| CN1586597A (zh) | 人参口腔崩解片及其制备工艺 | |
| CN1857587A (zh) | 一种清胃泻火,滋阴凉血的中药复方制剂及其制备方法 | |
| CN1586469A (zh) | 水飞蓟素口腔崩解片及其制备方法 | |
| CN1416879A (zh) | 一种降血脂中药 | |
| CN1660078A (zh) | 岩白菜素及复方岩白菜素的口腔崩解片及其制备工艺 | |
| CN1698666A (zh) | 双黄连泡腾片及制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 100083 A building, block 15, Tiangong building, No. 30, Haidian District, Beijing, Xueyuan Road Patentee after: COSCI MED-TECH Co.,Ltd. Address before: 100080, Haidian District satellite building, No. 63, Zhichun Road, Beijing, room 1410, Beijing Patentee before: COSCI MED-TECH Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060712 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |